Should an A-negative woman who has just had a miscarriage receive RhIg?

An A-negative woman who has just had a miscarriage should receive Rh immunoglobulin (RhIg) if she does not have evidence of active Anti-D. In cases where an Rh-negative mother is exposed to Rh-positive fetal blood, as may occur during a miscarriage, there is the risk that the mother could develop anti-D antibodies against the Rh-positive cells. These antibodies could pose a risk in future pregnancies by causing hemolytic disease of the fetus and newborn (HDFN).

Administering RhIg helps to prevent the mother's immune system from producing these antibodies by neutralizing any Rh-positive red blood cells that may have crossed into her circulation. The critical factor is the absence of active Anti-D; if the woman has already formed these antibodies, RhIg would not be effective in preventing sensitization.

The other choices suggest circumstances that either misinterpret the use of RhIg in miscarriages or incorrectly assume conditions under which it is administered. RhIg is not limited to term pregnancies, thereby ruling out options that suggest it is only used in such cases. It is also not dependent on knowing the baby’s blood type, as the primary concern is the mother's blood type and potential exposure to Rh-positive cells. Therefore, it is correct to state that RhIg